再回顾一下ICH Q7a 11.7的条款:
11.7.0 The packaging and holding of reserve samples is for the purpose of potential future evaluation of the quality of batches of API and not for future stability testing purposes.
11.7.2 The reserve sample should be stored in the same packaging system in which the API is stored or in one that is equivalent to or more protective than the marketed packaging system. Sufficient quantities should be retained to conduct at least two full compendial analyses or, when there is no pharmacopoeial monograph, two full specification analyses.
对于原料药来说,很明确,与楼主强调的观点是一致的,就是为了将来的质量追溯。另外,出于这个根本目的,Q7也提出可以留样可以采用更具保护性的包装系统。我理解,不仅仅是包装系统,还有存储条件。留样的目的是为了质量追溯,所以最大程度的保存留样最初的质量状态,尽可能的提供保护性,这是有意义的。去年与几个GMP检查员讨论到这个问题时,他们仍然不太认同我的观点。